NCT06220838View on ClinicalTrials.gov

Study SC-101 in Subjects With Advanced Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 2, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

SC-101

All subjects will receive a single intravenous (IV) infusion of SC-101 once weekly.

Trial Locations (5)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

Unknown

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin ConjuStar Biologics Co., Ltd.

INDUSTRY